<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34974792</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TRIM55 suppresses malignant biological behavior of lung adenocarcinoma cells by increasing protein degradation of Snail1.</ArticleTitle>
        <Pagination>
          <StartPage>17</StartPage>
          <EndPage>26</EndPage>
          <MedlinePgn>17-26</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2021.2004835</ELocationID>
        <Abstract>
          <AbstractText>Up until now, cancer refractoriness and distal organ metastatic disease remain as major obstacles for oncologists to achieve satisfactory therapeutic effects for lung adenocarcinoma patients. Previous studies indicated that TRIM55, which participates in the natural development of muscle and cardiovascular system, plays a protective role in hepatocellular carcinoma (HCC) pathogenesis. Therefore, in this study, we aimed to unveil the detailed molecular mechanism of TRIM55 and identify the potential target for lung adenocarcinoma patients. Surgical samples and lung cancer cell lines were collected to detect the TRIM55 expression for patients with or without lymph node/distal organ metastasis. Cellular functional assays including transwell assay, wound healing assay, cellular survivability assay, etc. as well as ubiquitination assay were performed to evaluate the impact of TRIM55/Snail1 regulatory network via the UPP pathway on lung cancer tumor cell migration and chemo-resistance. Lung cancer tissues and tumor cell lines exhibited significantly lower levels of TRIM55 expression. Functional study further indicated that TRIM55 inhibited chemo-resistance, migration, and cancer stem-cell like phenotype of tumor cells. Further detailed molecular experiments indicated that TRIM55 promoted degradation of Snail1 via the UPP pathway, which played an interesting role in the regulation of cancer cell malignancy. This study provided novel theory that TRIM55 acted as a potential tumor suppressor by inhibition of tumor cell malignancy through enhancement of Snail1 degradation via the UPP pathway. Our research will inspire further exploration on TRIM55 to promote therapeutic effects for lung adenocarcinoma patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Tianxing</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhenlong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Lihuan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Wenshu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wujin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yangyun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jianyuan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Xiaojie</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-5988-6841</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077192" MajorTopicYN="Y">Adenocarcinoma of Lung</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Lung adenocarcinoma</Keyword>
        <Keyword MajorTopicYN="Y">snail1</Keyword>
        <Keyword MajorTopicYN="Y">trim55</Keyword>
        <Keyword MajorTopicYN="Y">tumor suppressor</Keyword>
        <Keyword MajorTopicYN="Y">upp pathway</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34974792</ArticleId>
        <ArticleId IdType="pmc">PMC8812808</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2021.2004835</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A.. 
2021. 
Jan. Cancer Statistics. CA Cancer J Clin. 71(1):7–33. 10.3322/caac.21654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21654</ArticleId>
            <ArticleId IdType="pubmed">33433946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams DE, Pairolero PC, Davis CS, Bernatz PE, Spencer Payne W, Taylor WF, Uhlenhopp MA, Fontana RS. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg. 1981. 
Jul;82(1):70–76. doi:10.1016/S0022-5223(19)39389-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-5223(19)39389-4</ArticleId>
            <ArticleId IdType="pubmed">7242135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Adjei AA. 2015. 
Jun. Lung cancer and metastasis: new opportunities and challenges. Cancer Metastasis Rev. 34(2):169–171. 10.1007/s10555-015-9562-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-015-9562-4</ArticleId>
            <ArticleId IdType="pubmed">25956388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perera S, Holt MR, Mankoo BS, Gautel M. 2011. 
Mar
1. Developmental regulation of MURF ubiquitin ligases and autophagy proteins nbr1, p62/SQSTM1 and LC3 during cardiac myofibril assembly and turnover. Dev Biol. 351(1):46–61. 10.1016/j.ydbio.2010.12.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ydbio.2010.12.024</ArticleId>
            <ArticleId IdType="pmc">PMC3047806</ArticleId>
            <ArticleId IdType="pubmed">21185285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Huang L, Gao W. Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2). Medical Sci Monitor: Int Medical J Exp Clinical Res. 2019. 
Jan
27;25:771–777. doi:10.12659/msm.910984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/msm.910984</ArticleId>
            <ArticleId IdType="pmc">PMC6360872</ArticleId>
            <ArticleId IdType="pubmed">30685767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leng Z, Xia Q, Chen J, Li Y, Xu J, Zhao E, Zheng H, Ai W, Dong J. 2018. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer. Cell Physiol Biochem. 46(2):860–872. 10.1159/000488743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000488743</ArticleId>
            <ArticleId IdType="pubmed">29627827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question?
Am J Transl Res. 2013. 
Sep
25;5(6):563–581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3786264</ArticleId>
            <ArticleId IdType="pubmed">24093054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R, et al. 2008. 
Mar. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15(3):504–514. DOI:10.1038/sj.cdd.4402283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4402283</ArticleId>
            <ArticleId IdType="pubmed">18049477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. 
Nov
18. Identification of human brain tumour initiating cells. Nature. 432(7015):396–401. 10.1038/nature03128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03128</ArticleId>
            <ArticleId IdType="pubmed">15549107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, Camussi G. 2005. 
Feb. Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 166(2):545–555. 10.1016/s0002-9440(10)62276-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0002-9440(10)62276-6</ArticleId>
            <ArticleId IdType="pmc">PMC1602314</ArticleId>
            <ArticleId IdType="pubmed">15681837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D. 2005. 
Jan. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319(1):15–26. 10.1007/s00441-004-1018-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-004-1018-z</ArticleId>
            <ArticleId IdType="pubmed">15558321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu H, Li R, Liu Z, Zhang J, Luo R. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2013;6(11):2644–2650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3816842</ArticleId>
            <ArticleId IdType="pubmed">24228135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida A, Hsu LC, Davé V. 1992. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 46(4–5):239–244. 10.1159/000468794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000468794</ArticleId>
            <ArticleId IdType="pubmed">1292933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. 2009. 
Apr
15. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69(8):3382–3389. 10.1158/0008-5472.Can-08-4418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.Can-08-4418</ArticleId>
            <ArticleId IdType="pmc">PMC2789401</ArticleId>
            <ArticleId IdType="pubmed">19336570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al. 2009. 
Mar. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Molecular Cancer Res: MCR. 7(3):330–338. DOI:10.1158/1541-7786.Mcr-08-0393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.Mcr-08-0393</ArticleId>
            <ArticleId IdType="pmc">PMC4255559</ArticleId>
            <ArticleId IdType="pubmed">19276181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. 2007. 
Nov. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1(5):555–567. DOI:10.1016/j.stem.2007.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2007.08.014</ArticleId>
            <ArticleId IdType="pmc">PMC2423808</ArticleId>
            <ArticleId IdType="pubmed">18371393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene C, Collura V, Harpon J, Battaglia V, Vivat V, Sippl W, et al. 2012. 
Apr
20. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol. 19(4):467–477. 10.1016/j.chembiol.2012.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2012.02.007</ArticleId>
            <ArticleId IdType="pubmed">22520753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yau RG, Doerner K, Castellanos ER, Haakonsen DL, Werner A, Wang N, Yang XW, Martinez-Martin N, Matsumoto ML, Dixit VM, et al. 2017. 
Nov
2. Assembly and Function of Heterotypic Ubiquitin Chains in Cell-Cycle and Protein Quality Control. Cell. 171(4):918–933.e20. 10.1016/j.cell.2017.09.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.040</ArticleId>
            <ArticleId IdType="pmc">PMC5669814</ArticleId>
            <ArticleId IdType="pubmed">29033132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heger K, Wickliffe KE, Ndoja A, Zhang J, Murthy A, Dugger DL, Maltzman A, de Sousa E Melo F, Hung J, Zeng Y, et al. 2018. 
Jul. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature. 559(7712):120–124. DOI:10.1038/s41586-018-0256-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0256-2</ArticleId>
            <ArticleId IdType="pubmed">29950720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Q, Jin J, Hu H, Li HS, Romano S, Xiao Y, Nakaya M, Zhou X, Cheng X, Yang P, et al. 2014. 
Jun. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol. 15(6):562–570. DOI:10.1038/ni.2885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2885</ArticleId>
            <ArticleId IdType="pmc">PMC4032322</ArticleId>
            <ArticleId IdType="pubmed">24777531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeman MK, Lin JR, Freire R, Cimprich KA. 2014. 
Jul
21. DNA damage-specific deubiquitination regulates Rad18 functions to suppress mutagenesis. J Cell Biol. 206(2):183–197. 10.1083/jcb.201311063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201311063</ArticleId>
            <ArticleId IdType="pmc">PMC4107794</ArticleId>
            <ArticleId IdType="pubmed">25023518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Q, Wang Q, Cai R, Yuan H, Xu M. 2020. The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 25(1):1. 10.1186/s11658-019-0193-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s11658-019-0193-6</ArticleId>
            <ArticleId IdType="pmc">PMC6966813</ArticleId>
            <ArticleId IdType="pubmed">31988639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrallo-Gimeno A, Nieto MA. 2005. 
Jul. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development (Cambridge, England). 132(14):3151–3161. 10.1242/dev.01907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.01907</ArticleId>
            <ArticleId IdType="pubmed">15983400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang H-S, Cai S-H, Du J. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol. 2014. 
Jan
15;723:156–166. doi:10.1016/j.ejphar.2013.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2013.12.004</ArticleId>
            <ArticleId IdType="pubmed">24333218</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
